1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 71 results.

Thumbnail for Does triple trisomy (+4, +10, +17) remain prognostically significant factor in pediatric high hyperdiploid acute lymphoblastic leukemia (HD-ALL)?

ALL - 428

Does triple trisomy (+4, +10, +17) remain prognostically significant factor in pediatric high hyperdiploid acute lymphoblastic leukemia (HD-ALL)?

Elza Lomaia

Poster Presenter: Elza Lomaia

Thumbnail for Deconvolution of Peripheral Blood Transcriptomes to Evaluate Immune Profiles Associated With Measurable Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Machine Learning-Driven Study

ALL - 486

Deconvolution of Peripheral Blood Transcriptomes to Evaluate Immune Profiles Associated With Measurable Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Machine Learning-Driven Study

Fatima Aslam

Poster Presenter: Fatima Aslam

Thumbnail for Disparities in B-Lymphoblastic Lymphoma: Insights From 1275 Patients in the National Cancer Database Treated at Academic and Community Cancer Centers

ALL - 507

Disparities in B-Lymphoblastic Lymphoma: Insights From 1275 Patients in the National Cancer Database Treated at Academic and Community Cancer Centers

Oscar Hinojosa

Poster Presenter: Oscar Hinojosa

Thumbnail for Identifying Drivers of Patient-Reported Treatment Burden to Inform Symptom Management in Newly Diagnosed Ph+ ALL: Results from the Phase 3 PhALLCON Study

ALL - 514

Identifying Drivers of Patient-Reported Treatment Burden to Inform Symptom Management in Newly Diagnosed Ph+ ALL: Results from the Phase 3 PhALLCON Study

Christopher Dieyi

Poster Presenter: Christopher Dieyi

ALL - 576

Systematic Literature Review and Network Meta-Analyses of Hypersensitivity in Patients Receiving Asparaginase Treatment

Luke Maese

Poster Presenter: Luke Maese

Video

$Thumbnail for Safety and Preliminary Efficacy of Olverembatinib (HQP1351) Combined With Lisaftoclax (APG-2575) in Children and Adolescents With Relapsed/Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia: Results of a Phase 1b Study$

ALL - 584

Safety and Preliminary Efficacy of Olverembatinib (HQP1351) Combined With Lisaftoclax (APG-2575) in Children and Adolescents With Relapsed/Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia: Results of a Phase 1b Study

Jeffrey Rubnitz

Poster Presenter: Jeffrey Rubnitz

Thumbnail for Safety and Feasibility of the CALGB 10403 Pediatric-Inspired Regimen in Adults With Acute Lymphoblastic Leukemia Older Than 40 Years

ALL - 588

Safety and Feasibility of the CALGB 10403 Pediatric-Inspired Regimen in Adults With Acute Lymphoblastic Leukemia Older Than 40 Years

Manuel Alejandro Cruz-Martinez

Poster Presenter: Manuel Alejandro Cruz-Martinez

Thumbnail for Olverembatinib Combined With Blinatumomab in Patients With Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LBP) or Philadelphia Chromosome e-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)

ALL - 589

Olverembatinib Combined With Blinatumomab in Patients With Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LBP) or Philadelphia Chromosome e-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)

Elias Jabbour

Poster Presenter: Elias Jabbour

Thumbnail for Updated Results of POLARIS-1 (Part 1), a Global Registrational Phase 3 Study: Olverembatinib Combined With Low-Intensity Chemotherapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

ALL - 597

Updated Results of POLARIS-1 (Part 1), a Global Registrational Phase 3 Study: Olverembatinib Combined With Low-Intensity Chemotherapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Suning Chen

Poster Presenter: Suning Chen